solute carrier family 7 member 6 opposite strandGenealiases: EPM12 · Iwr1
Q-omics provides the consensus-scored SLC7A6OS profile across patient tissues and cancer cell-line models. SLC7A6OS expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SLC7A6OS is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SLC7A6OS RNA expression shows 20,240 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, HNSC, and ACC as cancer lineages where SLC7A6OS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC7A6OS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC7A6OS survival associations across molecular data types. SLC7A6OS RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC7A6OS RNA expression–survival associations across cancer types. High SLC7A6OS expression shows unfavorable associations in CESC, LUSC, LIHC and HNSC, but favorable associations in KIRC and UCS. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for SLC7A6OS RNA expression.
This table summarizes SLC7A6OS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC7A6OS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC7A6OS shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRP, COAD, BLCA and LIHC. The HNSC box plot shows higher SLC7A6OS RNA expression in tumor versus normal tissue (log2 FC = +0.977, t-test p < 0.001).
This table shows molecular features associated with SLC7A6OS in patient tissues and cancer cell lines. In patient samples, SLC7A6OS shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC7A6OS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
